Your browser doesn't support javascript.
loading
Zerumbone-incorporated liquid crystalline nanoparticles inhibit proliferation and migration of non-small-cell lung cancer in vitro.
Manandhar, Bikash; Paudel, Keshav Raj; Clarence, Dvya Delilaa; De Rubis, Gabriele; Madheswaran, Thiagarajan; Panneerselvam, Jithendra; Zacconi, Flavia C; Williams, Kylie A; Pont, Lisa G; Warkiani, Majid Ebrahimi; MacLoughlin, Ronan; Oliver, Brian Gregory; Gupta, Gaurav; Singh, Sachin Kumar; Chellappan, Dinesh Kumar; Hansbro, Philip M; Dua, Kamal.
Afiliación
  • Manandhar B; Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Sydney, NSW, 2007, Australia.
  • Paudel KR; Australian Research Centre in Complementary and Integrative Medicine, Faculty of Health, University of Technology Sydney, Sydney, NSW, 2007, Australia.
  • Clarence DD; Centre for Inflammation, Centenary Institute and University of Technology Sydney, Faculty of Science, School of Life Sciences, Sydney, NSW 2050, Australia.
  • De Rubis G; School of Postgraduate Studies, International Medical University (IMU), 57000, Kuala Lumpur, Malaysia.
  • Madheswaran T; Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Sydney, NSW, 2007, Australia.
  • Panneerselvam J; Australian Research Centre in Complementary and Integrative Medicine, Faculty of Health, University of Technology Sydney, Sydney, NSW, 2007, Australia.
  • Zacconi FC; Department of Pharmaceutical Technology, School of Pharmacy, International Medical University, 57000, Kuala Lumpur, Malaysia.
  • Williams KA; Department of Pharmaceutical Technology, School of Pharmacy, International Medical University, 57000, Kuala Lumpur, Malaysia.
  • Pont LG; Departamento de Química Orgánica, Facultad de Química y de Farmacia, Pontificia Universidad Católica de Chile, Av. Vicuña Mackenna 4860, 7820436, Macul, Santiago, Chile.
  • Warkiani ME; Centro de Investigación en Nanotecnología y Materiales Avanzados, CIEN-UC, Pontificia Universidad Católica de Chile, Av. Vicuña Mackenna 4860, 7820436, Macul, Santiago, Chile.
  • MacLoughlin R; Institute for Biological and Medical Engineering, Schools of Engineering, Medicine and Biological Sciences, Pontificia Universidad Católica de Chile, Santiago, Chile.
  • Oliver BG; Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Sydney, NSW, 2007, Australia.
  • Gupta G; Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, Sydney, NSW, 2007, Australia.
  • Singh SK; School of Biomedical Engineering, University of Technology Sydney, Sydney, New South Wales, Australia.
  • Chellappan DK; Institute for Biomedical Materials and Devices, Faculty of Science, University of Technology Sydney, Sydney, New South Wales, Australia.
  • Hansbro PM; Research and Development, Aerogen Limited, IDA Business Park, Galway, Connacht, H91 HE94, Ireland.
  • Dua K; School of Pharmacy & Biomolecular Sciences, Royal College of Surgeons in Ireland, Dublin, Leinster, D02 YN77, Ireland.
Naunyn Schmiedebergs Arch Pharmacol ; 397(1): 343-356, 2024 01.
Article en En | MEDLINE | ID: mdl-37439806
Lung cancer is the second most prevalent type of cancer and is responsible for the highest number of cancer-related deaths worldwide. Non-small-cell lung cancer (NSCLC) makes up the majority of lung cancer cases. Zerumbone (ZER) is natural compound commonly found in the roots of Zingiber zerumbet which has recently demonstrated anti-cancer activity in both in vitro and in vivo studies. Despite their medical benefits, ZER has low aqueous solubility, poor GI absorption and oral bioavailability that hinders its effectiveness. Liquid crystalline nanoparticles (LCNs) are novel drug delivery carrier that have tuneable characteristics to enhance and ease the delivery of bioactive compounds. This study aimed to formulate ZER-loaded LCNs and investigate their effectiveness against NSCLC in vitro using A549 lung cancer cells. ZER-LCNs, prepared in the study, inhibited the proliferation and migration of A549 cells. These inhibitory effects were superior to the effects of ZER alone at a concentration 10 times lower than that of free ZER, demonstrating a potent anti-cancer activity of ZER-LCNs. The underlying mechanisms of the anti-cancer effects by ZER-LCNs were associated with the transcriptional regulation of tumor suppressor genes P53 and PTEN, and metastasis-associated gene KRT18. The protein array data showed downregulation of several proliferation associated proteins such as AXL, HER1, PGRN, and BIRC5 and metastasis-associated proteins such as DKK1, CAPG, CTSS, CTSB, CTSD, and PLAU. This study provides evidence of potential for increasing the potency and effectiveness of ZER with LCN formulation and developing ZER-LCNs as a treatment strategy for mitigation and treatment of NSCLC.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Sesquiterpenos / Carcinoma de Pulmón de Células no Pequeñas / Nanopartículas / Neoplasias Pulmonares Límite: Humans Idioma: En Revista: Naunyn Schmiedebergs Arch Pharmacol Año: 2024 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Alemania
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Sesquiterpenos / Carcinoma de Pulmón de Células no Pequeñas / Nanopartículas / Neoplasias Pulmonares Límite: Humans Idioma: En Revista: Naunyn Schmiedebergs Arch Pharmacol Año: 2024 Tipo del documento: Article País de afiliación: Australia Pais de publicación: Alemania